Edoxaban: A Novel Factor Xa Inhibitor for the Management of Non-Valvular Atrial Fibrillation and Venous Thromboembolism

Kara A. Kubli, Jessica A. Snead, Angela Cheng-Lai

Research output: Contribution to journalArticle


Warfarin has been a highly prevalent agent for over 70 years; however, its use has been limited by drug-drug interactions, adverse events, and the need for frequent monitoring. To minimize these complications, several non-vitamin K oral anticoagulants have been approved, including the latest agent, edoxaban. Edoxaban is a factor Xa inhibitor approved for prevention of stroke/systemic embolism in patients with non-valvular atrial fibrillation and for the treatment of venous thromboembolism. Edoxaban was largely studied in the ENGAGE AF-TIMI 48 and Hokusai-VTE trials, both showing non-inferiority when compared to warfarin. Similar to other oral anticoagulants, the most serious adverse effects of edoxaban are related to bleeding. However, there are currently no approved reversal agents. Andexanet alfa and ciraparantag are the latest agents being studied for reversal. This article provides an overview of the safety and efficacy along with the advantages and disadvantages of edoxaban.

Original languageEnglish (US)
JournalCardiology in Review
Publication statusAccepted/In press - Mar 14 2016


ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this